Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus gasseri OLL2716
- Development stage
- Unknown
- Lead developer
- Meiji
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus gasseri OLL2716, commonly known as LG21, is a probiotic bacterial strain developed by Meiji Co., Ltd. It is specifically selected for its high acid tolerance, allowing it to survive the gastric environment and adhere to the gastric mucosa. The strain is widely marketed in Japan as a functional food product (yogurt) intended to suppress *Helicobacter pylori* colonization and alleviate symptoms of functional dyspepsia. Beyond its gastric applications, clinical research has investigated its potential to prevent small bowel injury induced by non-steroidal anti-inflammatory drugs (NSAIDs) like aspirin and to modulate intestinal dysbiosis. Its mechanism of action involves competitive inhibition of pathogens, production of lactic acid to lower local pH, and enhancement of the host's mucosal barrier function and immune response.
- Brand names
- Meiji Probio Yogurt LG21
- Other names
- Lactobacillus gasseri LG21
02
Targets
GMC (Gastrointestinal microbiota community)
Beyond the preview
Go deeper on Lactobacillus gasseri OLL2716.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus gasseri OLL2716.